• Barcitinib for hospitalized COVID-19 patients • Non-randomized clinical trial
• Any adult patient hospitalized with moderate/severe COVID-19
• Barcitinib + standard care vs. standard care alone
• Primary outcome of clinical status after 15 days • Barcitinib 2 mg orally daily for 10 days (NCT04321993, 2020)